An interventional study of Oral Antiretroviral Therapy and albuvirtide in AIDS-related Lymphoma and HIV Infection, sponsored by Shanghai Public Health Clinical Center. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by Shanghai Public Health Clinical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to evaluate the efficacy and safety of different antiretroviral therapy (ART) strategies in adults with AIDS-related lymphoma (ARL) receiving anti-lymphoma treatment. The main questions it aims to answer are:
Does long-acting injectable ART, including albuvirtide (ABT) or long-acting cabotegravir/rilpivirine (CAB/RPV), improve virological suppression compared with oral ART during anti-lymphoma treatment? Do different ART strategies differ in immune recovery, virological failure, low-level viremia, and safety in patients with ARL?
Researchers will compare three treatment strategies-oral ART alone, oral ART plus long-acting albuvirtide (ABT), and long-acting cabotegravir/rilpivirine (CAB/RPV)-to determine whether long-acting injectable ART provides better virological control and comparable safety during lymphoma treatment.
Participants will:
Receive one of three ART strategies according to their clinical condition and treatment preference while receiving standard anti-lymphoma therapy.
Attend scheduled study visits at baseline and Weeks 4, 8, 12, 24, 36, and 48. Undergo plasma HIV-1 RNA testing, CD4+ T-cell count measurement, laboratory assessments, and safety evaluations throughout the 48-week follow-up period.
Be monitored for virological suppression, immune recovery, adverse events, and lymphoma-related clinical outcomes.
25 studies on the registry are indexed under Lymphoma, AIDS-Related; 2 are open to participants now.
This study's planned enrollment of 60 is above the median of 18 across 13 interventional studies indexed under Lymphoma, AIDS-Related.
Browse Lymphoma, AIDS-Related studies →Shanghai Public Health Clinical Center is the lead sponsor of 38 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Age ≥18 years. Confirmed infection. confirmed AIDS-related lymphoma. Receiving anti-lymphoma treatment. Able and willing to provide written .
Exclusion Criteria:
- Expected survival less than 6 months. Severe concomitant or uncontrolled comorbidity. Refusal to receive antiretroviral therapy or lymphoma treatment. to study medications. Inability to complete scheduled follow-up. Any condition considered unsuitable by the investigator.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive standard oral antiretroviral therapy throughout lymphoma treatment.
Drug: Oral Antiretroviral Therapy
Participants with viremia who agree to receive long-acting therapy will receive oral ART combined with intravenous albuvirtide.
Drug: Oral Antiretroviral Therapy · Drug: albuvirtide
Eligible participants will receive long-acting intramuscular cabotegravir and rilpivirine according to the approved dosing schedule.
Drug: Cabotegravir/Rilpivirine
Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) or Current Oral ART Regimen at lymphoma diagnosis
Albuvirtide 640 mg intravenously every 4 weeks for five doses.
long-acting intramuscular cabotegravir and rilpivirine according to the approved dosing schedule.
Virological Suppression Rate at Week 24
Percentage of participants achieving plasma HIV RNA \<50 copies/mL at Week 24.
Time frame: Week 24
CD4 Cell Count Change
Change from baseline in CD4+ T-cell count.
Time frame: Week 24 Week 48
Low-Level Viremia
Percentage of participants with HIV RNA between 50 and 200 copies/mL.
Time frame: Week 24 and Week 48
Virological Failure
Percentage of participants with HIV RNA ≥200 copies/mL.
Time frame: Week 24
Adverse Events
Incidence of adverse events and serious adverse events.
Time frame: Baseline through Week 48
Virological Suppression Rate at Week 48
Percentage of participants achieving plasma HIV RNA \<50 copies/mL at Week 48.
Time frame: Week 48.
Plan to share: No
Started May 2026 (actual). Primary completion is estimated for Jul 2028, 26 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Public Health Clinical Center